High-grade endometrial stromal sarcoma (HGESS) is a rare and aggressive uterine mesenchymal neoplasm characterized by recurrent YWHAE::NUTM2 fusions and BCOR alterations. In this study, we performed integrated genomic and transcriptomic profiling of 45 HGESS and 23 low-grade endometrial stromal sarcoma (LGESS) cases to systematically characterize and compare their clinicopathological features, genomic alterations, transcriptomic profiles, immune microenvironments, and prognostic characteristics, and to explore potential subtype-specific therapeutic opportunities. Among the 45 HGESS cases, 26 underwent targeted DNA panel sequencing and 33 underwent whole-transcriptome sequencing (WTS). Among the 23 LGESS cases, 15 underwent targeted DNA panel sequencing and 11 underwent WTS.
No takes yet. Share an insight, caveat, or question.
谭彦铭(Yanming Tan) (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: